



TEOSYAL REDENSITY®2 is a trademark of TEOXANE SA and it is a product of the range TEOYAL® PURESENSE.




THE EYE CONTOUR: A PROMINENT DEMAND / A CHALLENGING AREA TO TREAT

REDENSITY 2 UNDER EYE CIRCLE FIGHTER

WIN
THE ULTIMATE
BATTLE AGAINST
UNDER EYE
CIRCLES

An early and visible sign of facial ageing

- From the age of 30, 50% of women are concerned by the appearance of their under eye circles^{1,2}
- Eye contour continues to be one of the major aesthetic concerns for women throughout their lifetime^{1,2}
- It only is the 7th area corrected by aesthetic treatment¹




► Under eye circle correction is an under valued demand

A medical challenge with a complex anatomy³

High risk area due to:

- A delicate lymphatic system
- The angular artery
- The emergence of the infraorbital nerve (V₂)

Anatomical specificities of the suborbital area



To treat this area physicians need:

- A product with specific properties^{4,5}
- A fully mastered injection technique^{4,5}

* Results based on opinion from n=603 patients aged from 30-65 years old

// Eye contour correction, a tailored treatment for a specific need //

REDENSITY 2

THE 1ST GEL SPECIFICALLY DESIGNED
TO TACKLE UNDER EYE CIRCLES*

3-in-1 patented formula**

A gel with unique properties

- ▶ Low hygroscopy⁶
- ▶ Light consistency⁶
- ▶ Viscous with optimised cohesivity⁶
- ▶ Dermo stimulating^{7,8}
- ▶ Anesthetising


2 Cocktail of 14 essential nutrients naturally present in the skin

- 8 Amino Acids for cell regeneration & hydration (Leu, Ile, Val, Gly, Lys, Thr, Pro, Arg)
- 3 antioxidants for protection against free radicals (Glutathione, N-Acetyl-L-Cystein, Alpha-Lipoic Acid)
- 2 minerals (Zinc, Copper) and
- 1 Vitamin (B6) for cellular metabolism

3 Lidocaine 0.3%

1 High Molecular Weight Hyaluronic Acid (HA) mix:

- ▶ Crosslinked HA & Non crosslinked HA
- ▶ Total HA concentration (15 mg/mL)
- ▶ BDDE bonds



- ▶ Good safety & ease of injection^{9,10}
- ▶ Immediate & natural under eye correction^{9,10}
- ▶ Delayed ageing of the eye contour^{9,10}

Representation of REDENSITY 2 formula

A STATE-OF-THE-ART FILLER BASED ON THE REDENSITY FUNDAMENTALS



The tear trough has always been considered a difficult area to treat; both for its intrinsic nature and due to the difficulty in finding materials that are less hydrophilic. TEOSYAL® PureSense Redensity 2 can be used safely to achieve good results in this challenging area¹¹.



Prof. Giuseppe SITO,
M.D., Aesthetic Surgeon Milan, Turin and Naples

To improve safety & ease of injection

- Ideal viscoelasticity and gel cohesivity for a high spreadability & convenient positioning of the gel^{6,9,10}



Monophasic HA
24mg/g

Teosyal Redensity 2

Biphasic HA
20mg/g


- Lightweight with minimal gel swelling for low pressure on tissues and less risk of oedema^{6,9,10}

For immediate & natural correction^{6,9,10}

- Low hygroscopy for natural and reliable result:
Volume injected = Correction observed
- Viscous with enhanced cohesivity for filling efficiency

To delay skin ageing^{7,8,12}

- **Hydration & rejuvenation:** from the complementary actions of diffusible essential nutrients and High Molecular Weight HA
- **Redensification** of the papillary dermis & the dermoepidermal junction



Control

HA + Essential Nutrient Cocktail

Skin explants at day 9 post-injection

And more than that...

- ▶ Dermoepidermal junction strengthening - Increased elasticity and firmness
 - +98% Collagen IV (elasticity & tissue cohesion)
 - +26% Fibrillin-1 (tensor effect)
- ▶ Antioxidant effect
 - -28% malondialdehyde (oxidative stress marker)
- ▶ Skin Hydration
 - x14 epidermal glycoaminoglycan production

A CLINICALLY OBSERVED EFFICACY ON THE UNDER EYE CIRCLE



It is well-known that the hygroscopic effect of HA is to retain water, making the treatment of this area difficult. Currently we have a specific HA, TEOSYAL® PureSense Rendensity 2, faintly hygroscopic, specifically designed to treat tear troughs and to correct them naturally on the long-term¹³.




Dr. Natalia RIBE,
M.D. Aesthetic Doctor & Andrologist Barcelona Spain.

An efficacy observed by 33 physicians and 151 patients**


High improvement of under eye circles^{9,10}

99% of patients and physicians perceived an aesthetic improvement of the tear trough within 1 month post-injection



Recognised skin quality improvement^{9,10}

% of patients with satisfactory to very satisfactory skin quality improvement one month post-injection




Immediate & visible under eye circle correction



Long lasting global satisfaction¹⁴

Evaluation of the overall aesthetic results by physicians and patients, over 12 months (% of improved scores on the Global Aesthetic Improvement Scale*)



** Multicentric and international study: 2012/2013. 33 practitioners, 151 patients (86% of women and 14% of men). Visit 1 (T0): Injection, Visit 2 (T30days): Control and evaluation. Indications: 93% of patients were injected in the tear trough area.


* based on GAIS: Global Aesthetic Improvement Scale.

// You won't believe your eyes //

A PROVEN PATIENTS' AND PHYSICIANS' SATISFACTION

Safety recognised in a clinical trial^{9,10#}

75% of the patients reported no adverse event within 1 month post-injection




Most side effects reported were mild, temporary and correctable

During the clinical trial**:

- Mainly mild and transient post-injection reactions
- No blue discoloration / Tyndall effect (> 1 month)
- No need for hyaluronidase
- No unpleasant malar swelling
- No extra local anaesthetics required

An easy injection for a reliable practice^{9,10}

Ease of injection reported by 98% of physicians



High global patient satisfaction levels^{9,10}

- 97 % of patients were satisfied
- 98 % of patients would recommend the procedure
- 97 % of patients would repeat the treatment

Comparison of the safety with published literature. Side effects of the treatment: 11% bruising is significantly lower than the 27% reported by (15). 2.6% initial blue discoloration is lower than the 5% reported by (16). Careful massage of the highly malleable gel ensures accurate spreading and prevents the lumpiness or surface irregularities observed in (16,17). 8% early transient oedema is substantially lower than previously reported (10).

** Multicentric and international study: 2012/2013. 33 practitioners, 151 patients (86% of women and 14% of men). Visit 1 (T0): Injection, Visit 2 (T30days): Control and evaluation. Indications: 93% of patients were injected in the tear trough area.

PROTOCOL: 4 KEY SUCCESS FACTORS


1 4 indications

- Under eye circle
- Tear trough
- Palpebromalar groove
- Minimal palpebral or malar bag

2 Careful clinical diagnosis* of the lower eyelid area¹⁸

Examine patient in a semi-sitting position

- **STEP 1 / Pressure test:** press the lower orbital margin to validate the absence of lymphatic stasis
- **STEP 2 / Snap-Back test:** check the absence of skin looseness at the lower eyelid level (grade 1)
- **STEP 3 / Positive vectors theory:** control the vector, the lower eyelid should have a negative vector



- **STEP 4 / Gel volume estimation:** ask the patient to look upwards then exert pressure on the malar bone

*Diagnosis at physician's discretion. Read instructions for use

⚠ Caution

CONTRAINDICATION¹⁹


- Lower eyelid looseness
- Lymphatic stasis
- Very serious depression in the tear trough
- Significant malar or palpebral bags

HIGH RISK AREAS^{3,18}

- 1 Angular artery
- 2 Emergence of the infraorbital nerve V₂ (see page 3)

3 Precise injection technique^{3,20}

- **SMALL volume** max 0.5mL per eye circle
- **SLOW injection**
- **DEEP supra-periosteal** / sub-orbicular injection



Anatomical section of the under eye area Microbolus technique with needle Retrograde technique with cannula

4 Protocol

- **First session:** under-correction is recommended
- **Touch-up session:** 1 month later, only if necessary

 Tutorial videos on TEOXANE's Youtube channel www.teoxane.com

FOR AN EASIER TREATMENT OF THE EYE CIRCLE: REDENSITY 2 + TEOSYAL®PEN



TEOSYAL® PURESENSE REDENSITY 2

A different gel designed for eye circles

- Mix of cross-linked and non cross-linked HA
HA concentration: 15 mg/mL
- Cross-linking: ●○○○○○
- Lidocaine 0.3%
- Essential Nutrient Complex
- Box of 2 x 1 mL syringes + 30G ½ needle

TEOSYAL REDENSITY® is a trademark of TEOXANE SA and it is a product of the range TEOSYAL® PURESENSE. TEOSYAL® PureSense Redensity 2 is a medical device, class III, and is regulated health product bearing the CE marking (CE0086) under this regulation. For more information, please refer to TEOSYAL® PureSense Redensity 2's instructions for use.



TEOSYAL®PEN

THE FIRST MOTORISED CORDLESS HA INJECTION SYSTEM

Let your art speak. Thanks to its ergonomic, lightweight design and homogenous filler delivery, TEOSYAL® PEN offers you a greater ease of injection in sensitive areas and a smoother experience for your patient.

TEOSYAL® PEN is a motorised and cordless device for hyaluronic acid injections in order to correct wrinkles and depressions. Manufactured by Juvaplus SA. This medical device (class IIa), is a regulated health product which bear, under this regulation, the CE mark (CE0434).

REFERENCES

1. Arcane Research Study – February 2011: study carried out in France among 4 402 women aged 18 to 75.
2. Narurkar, V., Shamban, A., Sissins, P., Stonehouse, A., Gallagher, C. Facial treatment preferences in aesthetically aware women. *Dermatol Surg.* 2015;41 Suppl 1:S153-60.
3. Bravo, BS., Rocha, CR., Bastos, JT., Silva PM., Comprehensive Treatment of Periorbital Region with Hyaluronic Acid. *J Clin Aesthet Dermatol.* 2015, 8(6):30-5.
4. Michaud, T., Gassia, V., Belhaouari, L. Facial dynamics and emotional expressions in facial aging treatments. *J Cosmet dermatol.* 2015, 14(1):9-21.
5. Bass, L. Injectable filler techniques for facial rejuvenation, volumization, and augmentation. *Facial Plast Surg Clin N Am.* 2015, 23:479-488.
6. Data on File. Torsion and compression tests assessed on a rheometer. The measurement of the rheological parameter Delta index represents the balance between gel viscosity and elasticity.
7. Study report 10E2047 TEOSYAL® PureSense Redensity (I) on human skin explants carried out by BIO-EC for Teoxane, 2010.
8. Complementary analysis of the study 10E2047 TEOSYAL® PureSense Redensity (I). Assessment of TEOSYAL® PureSense efficacy on skin rejuvenation and protection: study carried out by an independent laboratory, on the measure of the outcomes of injecting a product bolus in the dermis of human skin explants. This skin model system highlights the effects of TEOSYAL® PureSense Redensity (I) on skin biological markers.
9. Multicentric and international study: 2012/2013. 33 practitioners, 151 patients (86% of women and 14% of men (Mean age of 48 years old). Visit 1 (T0): Injection. Visit 2 (T30 days): Control and evaluation. Indications: 93% of patients were injected in the tear trough area, 5% in the crow's feet and 2% in the glabella. 58% of injections have been performed in contact with periosteum with a serial puncture technique and 42% of injections were deeper than the orbicularis muscle.

Injection ease: mean score 1.41 (1-very easy, 2-easy, 3-difficult, 4-very difficult): practitioners evaluation

Advert events: generally mild (78%), occasionally moderate (17%) or more severe (6%), n=112 patients available for safety interview within a month. Bruising was reported in 11% of the cases, but lasted for a median of 7 days. 2 cases of side effects of 15 days (1 bruising, 1 edema). Out of 4 patients displaying an initially noticeable blue discoloration, only 1 lasted for more than 13 days. The discoloration disappeared in less than one month and no treatment with hyaluronidase was required. 1 patient injected with a larger than recommended gel volume (1ml per each treated side) experienced an edema lasting for more than 30 days. No patient requested follow-up for lumpiness. No patient had malar swelling, an adverse event that is a usual and significant complication of periorbital filler injection and is responsible for patient dissatisfaction. Upon injection, additional local lidocaine anesthetic (mostly cream) was not routinely used and only requested in 20.8% of the cases.

TEOSYAL® PureSense Redensity (II) may potentially have side effects following injection, such as: erythema, oedema, pain at the point of injection, haematomas, itching, temporary loss of sensitivity around the injection area, dyschromia, abscesses, indurations, nodules.
10. Berguiga M, Galatoire O. Tear trough rejuvenation: a safety evaluation of the treatment by a semi-crosslinked Hyaluronic Acid filler. *Orbit.* 2017; 36 (1):22-26.
11. Petrou I. Teosyal PureSense Redensity (II) Successfully Corrects Tear Troughs. *Eur Aesthetic Guid.* 2013;(Autumn):2.
12. Study report 13E2855, Evaluation of the diffusion of injectable products on human skin explants ex vivo, carried out by BIO-EC for Teoxane, 2014.
13. Ribé N. Tear Trough Rejuvenation: Personal Atenea Technique. *Avant-Garde, The news mag by TEOXANE.* Geneva; 2015;4.
14. Multicentric clinical study of 60 patients followed during 1 year (2010). The majority of patients were satisfied with the results immediately after injection, at month-6 and month-12, and would recommend it to their relatives.
15. Goldberg, R.A. and D.Fiaschetti, Filling the periorbital hollows with hyaluronic acid gel: initial experience with 244 injections. *Ophthal Plast Reconstr Surg.* 2006. 22(5): p. 335-41; discussion 341-3.
16. Morley, A.M. and R.Malhotra, Use of hyaluronic acid filler for tear-trough rejuvenation as an alternative to lower eyelid surgery. *Ophthal Plast Reconstr Surg.* 2011. 27(2): p. 69-73.
17. Berros, P. Periorbital contour abnormalities: hollow eye ring management with hyalurostructure. *Orbit.* 2010. 29(2): p. 119-25.
18. Hester TR, Douglas T, Szczerba S. Decreasing complications in lower lid and midface rejuvenation: the importance of orbital morphology, horizontal lower lid laxity, history of previous surgery, and minimizing trauma to the orbital septum: a critical review of 269 consecutive cases. *Plast Reconstr Surg.* 2009;123(3):1037-49.
19. Shetty R. Under eye infraorbital injection technique: The best value in facial rejuvenation. *J Cosmet Dermatol.* 2014;13(1):79-84.
20. Gold M. The science & art of hyaluronic acid dermal filler use in esthetic applications. *J Cosmet Dermatol.* 2009;8:301-7.



In today's world, beauty is no longer a question of age. Women want their beauty to last into the future.

That's why TEOXANE Laboratories specialise in the complex development of hyaluronic acid injectable gels with researchers driven by the culture of excellence and innovation as well as a total dedication to effectiveness and safety. Thanks to this approach, the hyaluronic acid gels we produce in our Geneva-based laboratories are of the highest quality and purity.

Mrs Valérie Taupin
CEO & Founder, TEOXANE